Done.

Done sells FDA-approved stimulant and non-stimulant medications for ADHD, prescribed and managed through its telehealth platform. The service is priced at a mid-range level: an initial psychiatric evaluation is $199, follow-up visits are $99, and medications are filled at standard pharmacy copays or cash prices. Sales and care delivery are 100 % online; patients complete intake, book video appointments, and receive e-prescriptions sent to local pharmacies. The brand’s core promise is same-week access to licensed ADHD specialists who can titrate and refill controlled substances without in-person visits. Done automates reminders, 24-hour provider messaging, and seamless pharmacy integration, positioning itself as a faster alternative to traditional psychiatric waitlists. Its best-known offering is the monthly membership that includes unlimited dosage adjustments and prior-authorization support. Target customers are 18-45-year-old adults who suspect or have confirmed ADHD and want convenient, stigma-free pharmacologic treatment. They value speed, digital convenience, and continuity of care over therapy add-ons. Many are students, remote workers, or entrepreneurs who see medication optimization as a productivity lever. Done competes with both brick-and-mortar psychiatry practices and emerging tele-mental-health platforms. It differentiates by focusing narrowly on ADHD medication management rather than broad therapy bundles, guaranteeing sub-seven-day appointment availability, and maintaining a clinician network licensed to prescribe Schedule II controlled substances nationwide.